loading

なぜVigil Neuroscience Inc(VIGL)の株価が下がっていますか?

2025-04-04 の取引セッション中に、Vigil Neuroscience Inc (VIGL) 株の 8.35% 下落を確認しました。これは通常のボラティリティやさまざまな内部および外部要因に起因する可能性がありますが、当社では状況を積極的に監視しており、できるだけ早くタイムリーな最新情報を提供することに注意してください。
2023-11-17:

Vigil Neuroscience Stock (VIGL) dropped by 40.03% from $6.67 to $4.00 in the trading on Friday November 17, 2023. The reason why VIGL stock down today is due to the interim data from its Phase 2 IGNITE proof-of-concept clinical trial in patients with ALSP. The data, representing the first six patients following six months of treatment with 20 mg/kg of iluzanebart, supports the drug's safety and tolerability, and showed target engagement and downstream pharmacological activity, consistent with Phase 1 data. Directionally supportive changes were observed on MRI and NfL biomarkers of disease progression in individual patients, and the company expects to report full Phase 2 IGNITE results in Q3 2024.

$66.10
price down icon 2.65%
$73.33
price down icon 0.15%
$31.60
price up icon 0.06%
$18.91
price down icon 11.53%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 7.93%
大文字化:     |  ボリューム (24 時間):